Akebia Therapeutics (NASDAQ:AKBA) Earns Overweight Rating from Analysts at JPMorgan Chase ...

Retrieved on: 2019-05-20 02:11:15

Tags for this article:

Click the tags to see associated articles and topics

Akebia Therapeutics (NASDAQ:AKBA) Earns Overweight Rating from Analysts at JPMorgan Chase .... View article details on hiswai:

Excerpt

<div><b>Baupost Group</b> LLC MA purchased a new stake in shares of Akebia Therapeutics in the 4th quarter valued at $135,327,000. BlackRock Inc. increased ...</div>

Article found on:

View Original Article